PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 529 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mom with Breast Cancer Who Had A Year to Live Goes... April 2, 2019 Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 Opinion: “There’s cause for optimism in 2021 and beyond” December 30, 2020 Teen Gets Bullied After Series Of Drastic Growth Spurts, Now She... September 18, 2019 Load more HOT NEWS April is Occupational Therapy (OT) Month- What is OT and how... Νέα για τον καρκίνο του προστάτη EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia
